APRE vs. IKNA, INCR, ANL, AVTE, PMVP, AVTX, UNCY, VIGL, CLSD, and ANIX
Should you be buying Aprea Therapeutics stock or one of its competitors? The main competitors of Aprea Therapeutics include Ikena Oncology (IKNA), InterCure (INCR), Adlai Nortye (ANL), Aerovate Therapeutics (AVTE), PMV Pharmaceuticals (PMVP), Avalo Therapeutics (AVTX), Unicycive Therapeutics (UNCY), Vigil Neuroscience (VIGL), Clearside Biomedical (CLSD), and Anixa Biosciences (ANIX). These companies are all part of the "pharmaceutical products" industry.
Aprea Therapeutics vs.
Ikena Oncology (NASDAQ:IKNA) and Aprea Therapeutics (NASDAQ:APRE) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, community ranking, media sentiment, profitability, analyst recommendations, risk, institutional ownership and dividends.
Aprea Therapeutics has lower revenue, but higher earnings than Ikena Oncology. Aprea Therapeutics is trading at a lower price-to-earnings ratio than Ikena Oncology, indicating that it is currently the more affordable of the two stocks.
Ikena Oncology has a net margin of 0.00% compared to Aprea Therapeutics' net margin of -1,029.50%. Ikena Oncology's return on equity of -36.88% beat Aprea Therapeutics' return on equity.
Ikena Oncology has a beta of 0.49, suggesting that its stock price is 51% less volatile than the S&P 500. Comparatively, Aprea Therapeutics has a beta of 0.75, suggesting that its stock price is 25% less volatile than the S&P 500.
75.0% of Ikena Oncology shares are owned by institutional investors. Comparatively, 34.2% of Aprea Therapeutics shares are owned by institutional investors. 5.9% of Ikena Oncology shares are owned by company insiders. Comparatively, 12.8% of Aprea Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Ikena Oncology presently has a consensus target price of $3.00, suggesting a potential upside of 100.00%. Aprea Therapeutics has a consensus target price of $15.50, suggesting a potential upside of 302.60%. Given Aprea Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Aprea Therapeutics is more favorable than Ikena Oncology.
Aprea Therapeutics received 25 more outperform votes than Ikena Oncology when rated by MarketBeat users. However, 58.82% of users gave Ikena Oncology an outperform vote while only 56.70% of users gave Aprea Therapeutics an outperform vote.
In the previous week, Aprea Therapeutics had 4 more articles in the media than Ikena Oncology. MarketBeat recorded 4 mentions for Aprea Therapeutics and 0 mentions for Ikena Oncology. Aprea Therapeutics' average media sentiment score of 0.20 beat Ikena Oncology's score of -1.00 indicating that Aprea Therapeutics is being referred to more favorably in the news media.
Summary
Aprea Therapeutics beats Ikena Oncology on 10 of the 18 factors compared between the two stocks.
Get Aprea Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for APRE and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aprea Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:APRE) was last updated on 1/20/2025 by MarketBeat.com Staff
Free APRE Stock Alerts